These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22046345)

  • 41. Trends in drug resistance prevalence in HIV-1-infected children in Madrid: 1993 to 2010 analysis.
    de Mulder M; Yebra G; Navas A; Martin L; de Jose MI; Navarro ML; de Ory SJ; Gonzalez-Granado I; Mellado MJ; Ramos JT; Holguin A
    Pediatr Infect Dis J; 2012 Nov; 31(11):e213-21. PubMed ID: 22785049
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of transmitted HIV-1 drug resistance among treatment-naive individuals in China, 2000-2016.
    Yuan H; Liu Z; Wu X; Wu M; Fang Q; Zhang X; Shi T; Tully DC; Zhang T
    Arch Virol; 2021 Sep; 166(9):2451-2460. PubMed ID: 34195923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
    Weng YW; Chen IT; Tsai HC; Wu KS; Tseng YT; Sy CL; Chen JK; Lee SS; Chen YS
    BMC Infect Dis; 2019 Aug; 19(1):741. PubMed ID: 31443633
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreasing prevalence of transmitted drug resistance among ART-naive HIV-1-infected patients in Iceland, 1996-2012.
    Sallam M; Şahin GÖ; Indriðason H; Esbjörnsson J; Löve A; Widell A; Gottfreðsson M; Medstrand P
    Infect Ecol Epidemiol; 2017; 7(1):1328964. PubMed ID: 28649306
    [No Abstract]   [Full Text] [Related]  

  • 45. Brazilian network for HIV Drug Resistance Surveillance (HIV-BresNet): a survey of treatment-naive individuals.
    Arruda MB; Boullosa LT; Cardoso CC; da Costa CM; Alves CR; de Lima ST; Kaminski HT; Aleixo AW; Esposito AO; Cavalcanti AM; Riedel M; Couto-Fernandez JC; Ferreira SB; de Oliveira IC; Portal LE; Wolf HH; Fernandes SB; de M C Pardini MI; Feiteiro MV; Tolentino FM; Diaz RS; Lopes GI; Francisco RB; Véras NM; Pires AF; Franchini M; Mesquita F; Tanuri A;
    J Int AIDS Soc; 2018 Mar; 21(3):. PubMed ID: 29504269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of drug-resistant HIV type 1 at the time of initiation of antiretroviral therapy in Portland, Oregon.
    MacVeigh MS; Kosmetatos MK; McDonald JE; Reeder JL; Parrish DA; Young TP
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):337-42. PubMed ID: 22697610
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV-1 transmitted drug resistance in Slovenia and its impact on predicted treatment effectiveness: 2011-2016 update.
    Lunar MM; Židovec Lepej S; Tomažič J; Vovko TD; Pečavar B; Turel G; Maver M; Poljak M
    PLoS One; 2018; 13(4):e0196670. PubMed ID: 29698470
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of HIV-1 transmitted drug resistance in the incarcerated population.
    Sapozhnikov J; Young JD; Patel M; Chiampas TD; Vaughn P; Badowski ME
    HIV Med; 2017 Nov; 18(10):756-763. PubMed ID: 28585361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. National prevalence and trends of HIV transmitted drug resistance in Mexico.
    Avila-Ríos S; García-Morales C; Garrido-Rodríguez D; Ormsby CE; Hernández-Juan R; Andrade-Villanueva J; González-Hernández LA; Torres-Escobar I; Navarro-Álvarez S; Reyes-Terán G;
    PLoS One; 2011; 6(11):e27812. PubMed ID: 22110765
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals.
    Vahabpour R; Bokharaei-Salim F; Kalantari S; Garshasbi S; Monavari SH; Esghaei M; Memarnejadian A; Fakhim A; Keyvani H
    Arch Virol; 2017 Jun; 162(6):1477-1485. PubMed ID: 28181034
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis.
    Avila-Rios S; Sued O; Rhee SY; Shafer RW; Reyes-Teran G; Ravasi G
    PLoS One; 2016; 11(6):e0158560. PubMed ID: 27355626
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stable level of HIV transmitted drug resistance in Estonia despite significant scale-up of antiretroviral therapy.
    Soodla P; Huik K; Pauskar M; Cuypers L; Van Laethem K; Rajasaar H; Kallas E; Lepa H; Velts-Lindh A; Jõgeda EL; Lutsar I; Avi R
    Infect Genet Evol; 2019 Nov; 75():103901. PubMed ID: 31146045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV transmitted drug resistance in adult and pediatric populations in Panama.
    Castillo J; Arteaga G; Mendoza Y; Martínez AA; Samaniego R; Estripeaut D; Page KR; Smith RE; Sosa N; Pascale JM
    Rev Panam Salud Publica; 2011 Dec; 30(6):649-56. PubMed ID: 22358417
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses.
    Hauser A; Hofmann A; Meixenberger K; Altmann B; Hanke K; Bremer V; Bartmeyer B; Bannert N
    PLoS One; 2018; 13(11):e0206234. PubMed ID: 30408827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children.
    Boerma RS; Boender TS; Sigaloff KC; Rinke de Wit TF; van Hensbroek MB; Ndembi N; Adeyemo T; Temiye EO; Osibogun A; Ondoa P; Calis JC; Akanmu AS
    J Int AIDS Soc; 2016; 19(1):21140. PubMed ID: 27836020
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort.
    Bartmeyer B; Kuecherer C; Houareau C; Werning J; Keeren K; Somogyi S; Kollan C; Jessen H; Dupke S; Hamouda O;
    PLoS One; 2010 Oct; 5(10):e12718. PubMed ID: 20949104
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transmission of drug-resistant HIV-1 is stabilizing in Europe.
    Vercauteren J; Wensing AM; van de Vijver DA; Albert J; Balotta C; Hamouda O; Kücherer C; Struck D; Schmit JC; Asjö B; Bruckova M; Camacho RJ; Clotet B; Coughlan S; Grossman Z; Horban A; Korn K; Kostrikis L; Nielsen C; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Riva C; Ruiz L; Salminen M; Schuurman R; Sonnerborg A; Stanekova D; Stanojevic M; Vandamme AM; Boucher CA
    J Infect Dis; 2009 Nov; 200(10):1503-8. PubMed ID: 19835478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002-09.
    Burchell AN; Bayoumi AM; Rourke SB; Major C; Gardner S; Sandstrom P; Rachlis A; Taylor D; Mazzulli T; Fisher M; Brooks J;
    J Antimicrob Chemother; 2012 Nov; 67(11):2755-65. PubMed ID: 22833637
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increasing HIV-1 Drug Resistance Between 2010 and 2012 in Adults Participating in Population-Based HIV Surveillance in Rural KwaZulu-Natal, South Africa.
    Manasa J; Danaviah S; Lessells R; Elshareef M; Tanser F; Wilkinson E; Pillay S; Mthiyane H; Mwambi H; Pillay D; de Oliveira T
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):763-9. PubMed ID: 27002368
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe.
    Rahim S; Fredrick LM; da Silva BA; Bernstein B; King MS
    HIV Clin Trials; 2009; 10(2):94-103. PubMed ID: 19487179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.